San Diego based, Quivive Pharma (‘kee-veev’) is pioneering a revolutionary approach to combating the opioid crisis by combining currently available opioid analgesics with an FDA approved respiratory stimulant via the 505(b)(2) regulatory pathway to create a new generation of analgesic products that are safer than existing opioids and are abuse deterrent via all routes of administration.